Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01283997 · ClinicalTrials.gov registry record · Phase 2
Prevention of Treatment Induced Neuropathy in Multiple Myeloma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT01283997: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01283997 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 79 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01283997, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to see if Minocin® (minocycline) can help to control nerve damage that causes numbness and tingling in the hands and feet (neuropathy) in patients receiving thalidomide and/or bortezomib.
Interventions
- OTHER Placebo
- DRUG Minocycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2011-01-25 |
| Est. Completion | 2022-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01283997
The ClinicalTrials.gov registry entry for NCT01283997 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01283997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01283997 about?
NCT01283997 is a clinical study titled "Prevention of Treatment Induced Neuropathy in Multiple Myeloma". The goal of this clinical research study is to see if Minocin® (minocycline) can help to control nerve damage that causes numbness and tingling in the hands and feet (neuropathy) in patients receiving thalidomide and/or bortezomib.
What is the current status of trial NCT01283997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2011-01-25. Estimated completion is 2022-08-22.
What interventions are being tested in trial NCT01283997?
The interventions under investigation include: Placebo (OTHER), Minocycline (DRUG).
Who is sponsoring clinical trial NCT01283997?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.